Bovine herpesvirus 4 (BoHV-4) is a promising vector for the delivery and intracellular expression of recombinant antigens and can thus be considered as a new prototype vaccine formulation system. An interesting, and actively pursued, antigen in the context of human immunodeficiency virus (HIV) infection prophylaxis (and therapy) is the C-C chemokine receptor type 5 (CCR5) co-receptor, whose blockage by specific antibodies has been shown to inhibit both viral entry and cell-to-cell transmission of the virus. Building on our previous work on the BoHV-4 vector system, we have engineered and tested a replication-competent derivative of BoHV-4 (BoHV-4-CMV-hCCR5?TK) bearing a human CCR5 (hCCR5) expression cassette. We show here that CCR5 is indeed expressed at high levels in multiple types of BoHV-4-CMV-hCCR5?TK-infected cells. More importantly, two intravenous inoculations of CCR5-expressing BoHV-4 virions into rabbits led to the production of anti-CCR5 antibodies capable of reacting with the CCR5 receptor exposed on the surface of HEK293T cells through specific recognition of the amino-terminal region (aa 14-34) of the protein. Given the growing interest for anti-CCR5 immunization as an HIV control strategy and the many advantages of virus-based immunogen formulations (especially for poorly immunogenic or self-antigens), the results reported in this study provide preliminary validation of BoHV-4 as a safe viral vector suitable for CCR5 vaccination.

Induction of antihuman C-C chemokine receptor type 5 antibodies by a bovine herpesvirus type-4 based vector / Verna, Andrea Elizabeth; Franceschi, Valentina; Tebaldi, Giulia; Macchi, Francesca; Menozzi, Valentina; Pastori, Claudia; Lopalco, Lucia; Ottonello, Simone; Cavirani, Sandro; Donofrio, Gaetano. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 8:OCT(2017), p. 1402. [10.3389/fimmu.2017.01402]

Induction of antihuman C-C chemokine receptor type 5 antibodies by a bovine herpesvirus type-4 based vector

Franceschi, Valentina;Tebaldi, Giulia;Macchi, Francesca;Ottonello, Simone;Cavirani, Sandro;Donofrio, Gaetano
2017-01-01

Abstract

Bovine herpesvirus 4 (BoHV-4) is a promising vector for the delivery and intracellular expression of recombinant antigens and can thus be considered as a new prototype vaccine formulation system. An interesting, and actively pursued, antigen in the context of human immunodeficiency virus (HIV) infection prophylaxis (and therapy) is the C-C chemokine receptor type 5 (CCR5) co-receptor, whose blockage by specific antibodies has been shown to inhibit both viral entry and cell-to-cell transmission of the virus. Building on our previous work on the BoHV-4 vector system, we have engineered and tested a replication-competent derivative of BoHV-4 (BoHV-4-CMV-hCCR5?TK) bearing a human CCR5 (hCCR5) expression cassette. We show here that CCR5 is indeed expressed at high levels in multiple types of BoHV-4-CMV-hCCR5?TK-infected cells. More importantly, two intravenous inoculations of CCR5-expressing BoHV-4 virions into rabbits led to the production of anti-CCR5 antibodies capable of reacting with the CCR5 receptor exposed on the surface of HEK293T cells through specific recognition of the amino-terminal region (aa 14-34) of the protein. Given the growing interest for anti-CCR5 immunization as an HIV control strategy and the many advantages of virus-based immunogen formulations (especially for poorly immunogenic or self-antigens), the results reported in this study provide preliminary validation of BoHV-4 as a safe viral vector suitable for CCR5 vaccination.
2017
Induction of antihuman C-C chemokine receptor type 5 antibodies by a bovine herpesvirus type-4 based vector / Verna, Andrea Elizabeth; Franceschi, Valentina; Tebaldi, Giulia; Macchi, Francesca; Menozzi, Valentina; Pastori, Claudia; Lopalco, Lucia; Ottonello, Simone; Cavirani, Sandro; Donofrio, Gaetano. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 8:OCT(2017), p. 1402. [10.3389/fimmu.2017.01402]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2839739
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact